Intracellular Bacterial Vaccine

About Gylden Pharma

Gylden Pharma, formerly known as Emergex, is a private biotechnology company advancing a novel platform of T cell-priming vaccines. Its technology combines immunoproteomics, a nanocluster delivery system, and a microneedle array patch to target conserved viral peptides, aiming for broad, variant-resistant, and durable immunity. The company's lead candidate for Betacoronaviruses has been selected for NIH/NIAID Project NextGen clinical trials, positioning it in the next-generation vaccine landscape against pandemic threats. With in-house GMP manufacturing and a clear focus on infectious diseases, Gylden is targeting some of the world's most pressing immunological challenges.

Therapeutic Areas